Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
Research and development	$ 285,885	$ 248,626	$ 132,944
Research and development related success payments and contingent consideration	(84,882)	57,873	124,935
General and administrative	71,561	50,410	28,270
Total operating expenses	272,564	356,909	286,149
Loss from operations	(272,564)	(356,909)	(286,149)
Interest income, net	3,762	676	747
Other income (expense), net	(674)	305	97
Net loss	$ (269,476)	$ (355,928)	$ (285,305)
Net loss per common share - basic	$ (1.43)	$ (2.14)	$ (21.92)
Net loss per common share - diluted	$ (1.43)	$ (2.14)	$ (21.92)
Weighted-average number of common shares - basic	188,344	166,433	13,014
Weighted-average number of common shares - diluted	188,344	166,433	13,014